Eli Lilly doubles down on Irish operations with $1.8 bln Investment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Citi restarts coverage of Eli Lilly with Buy rating on increased tirzepatide forecasts
September 13, 2024 1:04 PM EDTCiti reinstated its coverage of Eli Lilly & Co. (NYSE: LLY) with a Buy rating and a target price of $1,060 per share in a note Friday.
The move follows a period during which the rating was suspended. The analysts at Citi have updated their projections for Eli Lilly, driven by enhanced forecasts for the company's tirzepatide,... More
